drugset / Trial / NCT02428270
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study (the second phase in testing a new drug or combination to see how effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib. The purpose of the study is to evaluate the antitumor activity of GSK2256098 and Trametinib in patients with advanced pancreatic cancer.
Timeline
- Start
- 2016-04
- Primary completion
- 2017-06
- Completion
- 2022-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2256098 | Small molecule | 0.375 mg | Oral |
| Subject | GSK2256098 | Small molecule | 0.5 mg | Oral |
| Subject | Trametinib | Small molecule | 250 mg | Oral |
| Subject | Trametinib | Small molecule | 500 mg | Oral |